Company
Who we are
What we do
Investor relations
News & key figures
Investor presentation
Xlife dates
ESG
Projects
Technology Platforms
Biotech and Therapies
Medical Technology
Artificial Intelligence
Contact
DE
Collaborative
Analyst coverage
Institute
Analyst
Target price
Report
Intron Health Research
Dominic Rose
47 CHF
view
Baader Bank
Amandeep Goyal
81 CHF
view
Stifel
Daniel Jelovcan
68 CHF
view
News
Press Releases
13.6.25
Strategic Alliance Between Xlife Sciences AG, JIPYONG LLC and JIPYONG IP to Accelerate Korean Life Sciences Ventures’ Access to Global Capital Markets
6.5.25
Xlife Sciences AG Announces Strategic Collaboration between Portfolio Company Firstgene Life Sciences and Hovione in the Field of Gene Therapy
19.12.24
Xlife Sciences AG Publishes 2023 ESG Report: A Continued Commitment to Sustainable Innovation
Archive
Ad hoc News
5.5.2025
Xlife Sciences AG confirms sustainable value development and strategic scaling of the portfolio in the 2024 Valuation Report
25.4.2025
Xlife Sciences AG publishes 2024 Annual Report: Strategic Expansion, Technological Milestones, and International Capital Market Presence
23.4.2025
From Lab to Unicorn: Xlife Sciences AG Portfolio Company VERAXA Biotech AG to merge with Voyager Acquisition Corp. listed on NASDAQ
Archive
Downloads
Financial Reports
May 5, 2025
Valuation Report 2024
April 25, 2025
Annual Report 2024
September 19, 2024
Half-Year Report 2024
April 30, 2024
Valuation Report 2023
April 23, 2024
Annual Report 2023
September 21, 2023
Half-Year Report 2023
April 27, 2023
Valuation Report 2022
April 20, 2023
Annual Report 2022
September 28, 2022
Half-Year Report 2022
May 9, 2022
Valuation Report 2021
April 29, 2022
Annual Report 2021
February 8, 2022
Interim financial statement Q3 2021 (only in german)
August 5, 2021
Semi-Annual Report 2021
Half-year results (only available in German)
May 29, 2020
Annual statement 2020
Sign up for our media releases